A phase I trial to evaluate repetitive intravenous doses of gadolinium texaphyrin [motexafin gadolinium] as a radiosensitizer in patients with glioblastoma multiforme
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics
- 02 Oct 2005 New trial record.